GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Level Four Advisory Services LLC

Level Four Advisory Services LLC boosted its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,455 shares of the company’s stock after buying an additional 187 shares during the quarter. Level Four Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $267,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GEHC. First Command Advisory Services Inc. boosted its holdings in GE HealthCare Technologies by 36,900.0% during the 3rd quarter. First Command Advisory Services Inc. now owns 370 shares of the company’s stock valued at $25,000 after acquiring an additional 369 shares during the period. ORG Partners LLC raised its stake in shares of GE HealthCare Technologies by 174.2% in the third quarter. ORG Partners LLC now owns 425 shares of the company’s stock valued at $29,000 after acquiring an additional 270 shares in the last quarter. Fortitude Family Office LLC acquired a new position in GE HealthCare Technologies during the 4th quarter worth $29,000. Turtle Creek Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies in the 4th quarter valued at about $30,000. Finally, Valued Wealth Advisors LLC purchased a new position in shares of GE HealthCare Technologies in the 4th quarter valued at about $33,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $80.62 on Thursday. The company has a current ratio of 1.06, a quick ratio of 0.83 and a debt-to-equity ratio of 1.11. The stock’s 50 day moving average is $85.49 and its two-hundred day moving average is $80.42. GE HealthCare Technologies Inc. has a twelve month low of $62.35 and a twelve month high of $94.50. The firm has a market capitalization of $36.80 billion, a PE ratio of 23.57, a P/E/G ratio of 2.95 and a beta of 1.26.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Tuesday, April 30th. The company reported $0.90 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.90. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. The company had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same period last year, the company posted $0.85 earnings per share. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Stockholders of record on Friday, April 19th were paid a dividend of $0.03 per share. The ex-dividend date of this dividend was Thursday, April 18th. This represents a $0.12 annualized dividend and a dividend yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio is presently 3.51%.

Wall Street Analyst Weigh In

GEHC has been the topic of several analyst reports. Argus raised their target price on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a report on Monday, April 1st. Morgan Stanley lifted their price objective on shares of GE HealthCare Technologies from $74.00 to $86.00 and gave the stock an “equal weight” rating in a research report on Monday, February 12th. HSBC initiated coverage on GE HealthCare Technologies in a research note on Thursday, February 15th. They issued a “buy” rating and a $100.00 price target on the stock. Mizuho lowered their price target on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Finally, UBS Group upgraded shares of GE HealthCare Technologies from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $66.00 to $88.00 in a research report on Monday, February 12th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.80.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, insider Frank R. Jimenez acquired 1,315 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was bought at an average price of $76.52 per share, with a total value of $100,623.80. Following the completion of the transaction, the insider now directly owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Frank R. Jimenez bought 1,315 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were acquired at an average cost of $76.52 per share, for a total transaction of $100,623.80. Following the acquisition, the insider now owns 75,796 shares in the company, valued at approximately $5,799,909.92. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jan Makela sold 66,955 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total value of $5,459,510.70. Following the completion of the transaction, the chief executive officer now owns 63,348 shares of the company’s stock, valued at approximately $5,165,395.92. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.